This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry

CompletedOBSERVATIONAL

Enrollment

255

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

Inflectra

1\. To describe the characteristics of patients newly initiated on Inflectra.

DRUG

Inflectra

2\. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.

Trial Locations (1)

Pfizer, Collegeville